Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 3, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the first part of its New Drug Application (NDA) for rolling review of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news